1,166,002 Shares in Health Catalyst, Inc. (NASDAQ:HCAT) Purchased by Kennedy Capital Management LLC

Kennedy Capital Management LLC bought a new stake in Health Catalyst, Inc. (NASDAQ:HCAT) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 1,166,002 shares of the company’s stock, valued at approximately $8,780,000. Kennedy Capital Management LLC owned approximately 1.98% of Health Catalyst at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Price T Rowe Associates Inc. MD grew its position in shares of Health Catalyst by 6.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 49,746 shares of the company’s stock valued at $375,000 after purchasing an additional 2,831 shares during the period. EntryPoint Capital LLC acquired a new stake in Health Catalyst in the 1st quarter worth about $98,000. Acadian Asset Management LLC grew its holdings in Health Catalyst by 38.3% in the 1st quarter. Acadian Asset Management LLC now owns 724,560 shares of the company’s stock valued at $5,453,000 after buying an additional 200,494 shares during the period. Gruss & Co. LLC purchased a new stake in Health Catalyst in the 1st quarter valued at about $188,000. Finally, Inspire Investing LLC acquired a new position in shares of Health Catalyst during the 1st quarter valued at about $355,000. 85.00% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Health Catalyst

In other Health Catalyst news, COO Daniel Lesueur sold 5,208 shares of the firm’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $6.15, for a total transaction of $32,029.20. Following the completion of the sale, the chief operating officer now owns 155,215 shares in the company, valued at approximately $954,572.25. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold a total of 8,564 shares of company stock valued at $54,889 in the last ninety days. Insiders own 2.70% of the company’s stock.

Health Catalyst Stock Performance

Shares of NASDAQ:HCAT traded down $0.06 during mid-day trading on Tuesday, hitting $7.63. 186,563 shares of the company traded hands, compared to its average volume of 590,058. The firm’s 50 day simple moving average is $6.62 and its 200 day simple moving average is $7.51. The firm has a market cap of $450.40 million, a P/E ratio of -4.12 and a beta of 1.32. Health Catalyst, Inc. has a 52-week low of $5.45 and a 52-week high of $14.37.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. Health Catalyst had a negative net margin of 35.56% and a negative return on equity of 11.86%. The company had revenue of $74.72 million for the quarter, compared to analyst estimates of $74.81 million. Equities research analysts expect that Health Catalyst, Inc. will post -0.4 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on HCAT shares. KeyCorp restated a “sector weight” rating on shares of Health Catalyst in a report on Wednesday, April 10th. Piper Sandler dropped their price objective on Health Catalyst from $15.00 to $14.00 and set an “overweight” rating for the company in a report on Thursday, June 6th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a report on Wednesday, April 10th. Evercore ISI dropped their price target on Health Catalyst from $9.00 to $8.00 and set an “outperform” rating for the company in a research note on Tuesday, July 9th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $11.00 price objective on shares of Health Catalyst in a report on Tuesday, May 21st. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $11.91.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.